Effect of combined electroacupuncture and medical therapy on insulin resistance in polycystic ovary syndrome patients

Submission date	Recruitment status	Prospectively registered
04/11/2020	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
18/11/2020	Completed	Results
Last Edited	Condition category	Individual participant data
17/11/2020	Nutritional, Metabolic, Endocrine	Record updated in last year

Plain English summary of protocol

Background and study aims

Polycystic ovary syndrome (PCOS) is a common condition that affects how a woman's ovaries work. It affects 7-10% of women worldwide. It is considered a serious problem as it lasts a lifetime and is not just tied to pregnancy. Electroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. This study aims to measure the effect of electroacupuncture and drug treatment on insulin resistance in PCOS patients.

Who can participate?

Women aged 18-40 with PCOS and body mass index (BMI) over 23 kg/m²

What does the study involve?

Participants are randomly allocated to be treated with electroacupuncture or sham electroacupuncture three times per week, with intervals of 1-2 days, for 12 times. The drug treatment used is metformin 2 x 500 mg per day. Blood samples are taken to measure insulin and blood glucose at the 1st and 12th session.

What are the possible benefits and risks of participating?

Participants could benefit from an improvement in insulin resistance. The risks include hematoma (collection of blood) at the point the acupuncture needle is inserted.

Where is the study run from?

University of Indonesia – Cipto Mangunkusumo Hospital (Indonesia)

When is the study starting and how long is it expected to run for? March 2018 to September 2018

Who is funding the study? investigator initiated and funded

Who is the main contact? R Muharam rmuharam@yahoo.com

Contact information

Type(s)

Public

Contact name

Mr R Muharam

Contact details

Jl. Pangeran Diponegoro No.71, Kenari, Kec. Senen Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta Indonesia 10430 +62 (0)812 85143491 rmuharam@yahoo.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

0248/UN2.F1/ETIK/2018

Study information

Scientific Title

Combination of electroacupuncture and pharmacological treatment in improving insulin resistance (HOMA-IR) in polycystic ovary syndrome patients: a double-blind randomized clinical trial

Study objectives

The combination of electroacupuncture and pharmacological therapy has better efficacy to improve insulin sensitivity.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 26/03/2018, Ethics Committee of the Faculty of Medicine, University of Indonesia (Jl. Salemba Raya no.6 Jakarta 10430, PO Box 1358; +62 (0)21 3912477; humas@fk.ui.ac.id, office@fk.ui.ac.id), ref: 18-03-0254

Study design

Double-blind randomized clinical trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Polycystic ovarian syndrome

Interventions

Randomization was done using a computer-based random block table randomizer. The doctors, paramedics, and laboratory personnel do not know whether the subject receives electroacupuncture or sham electroacupuncture. The participants also do not know whether they receive electroacupuncture or sham electroacupuncture.

Participants receive electroacupuncture three times per week, with intervals of 1-2 days, for 12 times. The pharmacological therapy used is metformin 2 x 500 mg per day.

Intervention Type

Other

Primary outcome measure

Median HOMA-IR index measured using initial fasting insulin and initial fasting blood glucose at the 1st and 12th session

Secondary outcome measures

- 1. Mean fasting blood glucose measured using a blood sample before and after intervention at the 1st and 12th session
- 2. Median fasting insulin measured using a blood sample before and after intervention at the 1st and 12th session

Overall study start date

26/03/2018

Completion date

20/09/2018

Eligibility

Key inclusion criteria

- 1. 18-40-year-old females
- 2. BMI >23 kg/m²
- 3. Volunteer to join and give informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

40 Years

Sex

Female

Target number of participants

44

Total final enrolment

44

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

29/03/2018

Date of final enrolment

19/09/2018

Locations

Countries of recruitment

Indonesia

Study participating centre

University of Indonesia – Cipto Mangunkusumo Hospital

Faculty of Medicine Jl. Pangeran Diponegoro No.71, Kenari, Kec. Senen Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta Indonesia

10430

Sponsor information

Organisation

University of Indonesia

Sponsor details

Division of Reproductive Immunoendocrinology Department of Obstetrics & Gynecology Jl. Pangeran Diponegoro No.71, Kenari, Kec. Senen Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta Indonesia 10430 +62 (0)812 85143491 rmuharam@yahoo.com

Sponsor type

University/education

Website

http://www.ui.ac.id/

ROR

https://ror.org/0116zj450

Funder(s)

Funder type

Other

Funder Name

investigator initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Intention to publish date

11/11/2020

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from R Muharam (rmuharam@yahoo.com).

IPD sharing plan summary

Available on request